Novartis' Kymriah Receives NICE Approval for R/R Diffuse Large B-cell lymphoma (DLBCL) in Adults
Shots:
- The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged <25 yrs. with B-cell acute lymphoblastic leukemia (ALL) in Sep-2018
- The P-II JULIET results; 18mos.@ median relapse-free survival rate 64%; OR 43%; safe and effective
- Kymriah is a CAR-T (chimeric antigen receptor T cell) therapy and has also received the US FDA approval for patients with relapsed/refractory (R/R) large B-cell lymphomas
Ref: Nice | Image: Wikipedia
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com